Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD
Open Access
- 28 October 2022
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (1) , 265-281
Abstract
Introduction Chronic kidney disease (CKD) is a serious condition associated with significant morbidity and healthcare costs. Despite this, early-stage CKD is often undiagnosed, and globally there is substantial variation in the effectiveness of screening and subsequent management. Microsimulations can estimate future epidemiological costs, providing useful insights for clinicians, policymakers and researchers. Inside CKD is a programme designed to analyse the projected prevalence and burden of CKD for countries across the world, and to simulate hypothetical intervention strategies that can then be assessed for potential impact on health and economic outcomes at a national and a global level. Methods Inside CKD uses a population-based approach that creates virtual individuals for a given country, with this simulated population progressing through a microsimulation in 1-year increments. A series of data inputs derived from national statistics and key literature defined the likelihood of a change in health state for each individual. Input modules allow for the input of nationally specific demographic and CKD status (including prevalence, diagnosis rates, disease stage and likelihood of renal replacement therapy), disease progression, critical comorbidities, and mortality. Health economics are reflected in cost data and a flexible intervention module allows for the testing of hypothetical policies—such as screening strategies—that may alter disease progression and outcomes. Results Using input data from the UK as a case study and a 6-year simulation period, Inside CKD estimated a prevalence of 9.2 million individuals (both diagnosed and estimated undiagnosed) with CKD by 2027 and a 5.0% increase in costs for diagnosed CKD and renal replacement therapy. External validation and sensitivity analyses confirmed the observed trends, substantiating the robustness of the microsimulation. Conclusions Using a microsimulation approach, Inside CKD extends the reach of current CKD policy analyses by factoring in multiple inputs that reflect national healthcare systems and enable analysis of the effect of multiple hypothetical screening scenarios on disease progression and costs.Keywords
Funding Information
- AstraZeneca
This publication has 35 references indexed in Scilit:
- Cost to government and society of chronic kidney disease stage 1–5: a national cohort studyInternal Medicine Journal, 2015
- Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)PLOS ONE, 2014
- Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT)BMC Nephrology, 2013
- Alarming predictions for obesity and non-communicable diseases in the Middle EastPublic Health Nutrition, 2013
- Model Transparency and ValidationMedical Decision Making, 2012
- Estimating the financial cost of chronic kidney disease to the NHS in EnglandNephrology Dialysis Transplantation, 2012
- Evaluating risk factor assumptions: a simulation-based approachBMC Medical Informatics and Decision Making, 2011
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference reportKidney International, 2011
- Dynamic Microsimulation Models for Health OutcomesMedical Decision Making, 2010
- Limited knowledge of kidney disease in a survey of AusDiab study participantsMedical Journal of Australia, 2008